598
Participants
Start Date
October 31, 2012
Primary Completion Date
August 31, 2014
Study Completion Date
August 31, 2014
Ceftazidime - Avibactam ( CAZ-AVI)
Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
Doripenem
500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
Research Site, Sylmar
Research Site, Royal Oak
Research Site, Lima
Research Site, Corrientes
Research Site, Córdoba
Research Site, Mendoza
Research Site, Santa Fe
Research Site, Belo Horizonte
Research Site, Campinas/SP
Research Site, Salvador
Research Site, São José Do Rio Preto - SP
Research Site, São Paulo
Research Site, Vila Clementino
Research Site, Pleven
Research Site, Rousse
Research Site, Sofia
Research Site, Zagreb
Research Site, Kyjov
Research Site, Opava
Research Site, Jena
Research Site, Wuppertal
Research Site, Athens
Research Site, Budapest
Research Site, Nagykanizsa
Research Site, Nyíregyháza
Research Site, Zalaegerszeg
Research Site, Jerusalem
Research Site, Petah Tikva
Research Site, Safed
Research Site, Fukuoka
Research Site, Koshigaya-shi
Research Site, Kyoto
Research Site, Nagoya
Research Site, Nara
Research Site, Ōita
Research Site, Sendai
Research Site, Sunto-gun
Research Site, Tokushima
Research Site, Ueda-shi
Research Site, Utsunomiya
Research Site, Guadalajara, Jalisco
Research Site, Inowrocław
Research Site, Krakow
Research Site, Warsaw
Research Site, Lisbon
Research Site, Brasov
Research Site, Bucharest
Research Site, Cluj-Napoca
Research Site, Craiova
Research Site, Iași
Research Site, Arkhangelsk
Research Site, Krasnodar
Research Site, Moscow
Research Site, Novosibirsk
Research Site, Penza
Research Site, Rostov-on-Don
Research Site, Saint Petersburg
Research Site, Saratov
Research Site, Vsevolozhsk
Research Site, Belgrade
Research Site, Kragujevac
Research Site, Poprad
Research Site, Prešov
Research Site, Trnava
Research Site, Žilina
Research Site, Busan
Research Site, Seoul
Research Site, Wŏnju
Research Site, Chiayi City
Research Site, Taipei
Research Site, Diyarbakır
Research Site, Cherkasy
Research Site, Dnipropetrovsk
Research Site, Kharkiv
Research Site, Kyiv
Research Site, Lviv
Research Site, Mykolaiv
Research Site, Odesa
Research Site, Uzhhorod
Research Site, Zaporizhzhya
Lead Sponsor
Collaborators (1)
Forest Laboratories
INDUSTRY
Pfizer
INDUSTRY